Biomedical Engineering Reference
In-Depth Information
3. Ben, F.R., Gross, E., Ben, A.S., Hassine, H., and Saguem, S. (2009): The
dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for
screening of dihydropyrimidine dehydrogenase deficiency in colorectal
cancer patients treated with 5-fluorouracil.
Pathol. Biol.(Paris)
, 57:
470-476.
4. Bocci, G., Barbara, C., Vannozzi, F., Di, P.A., Melosi, A., Barsanti,
G., Allegrini, G., Falcone, A., Del, T.M., and Danesi, R. (2006): A
pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Clin. Pharmacol. Ther.
, 80: 384-395.
5. Bocci, G., Di, P.A., Barbara, C., Masi, G., Fornaro, L., Loupakis, F., Allegrini,
G., Falcone, A., Del, T.M., and Danesi, R. (2009): Pharmacokinetics, a
main actor in a many-sided approach to severe 5-FU toxicity prediction.
Br. J. Clin. Pharmacol.
, 67: 132-134.
6. Capitain, O., Boisdron-Celle, M., Poirier, A.L., Abadie-Lacourtoisie,
S., Morel, A., and Gamelin, E. (2008): The influence of fluorouracil
outcome parameters on tolerance and efficacy in patients with
advanced colorectal cancer.
, 8: 256-267.
7. Ciccolini, J., Gross, E., Dahan, L., Lacarelle, B., and Mercier, C. (2010):
Routine dihydropyrimidine dehydrogenase testing for anticipating
5-fluorouracil-related severe toxicities: hype or hope?
Pharmacogenomics. J.
Clin. Colorectal
, 9: 224-228.
8. Ciccolini, J., Mercier, C., Evrard, A., Dahan, L., Boyer, J.C., Duffaud, F.,
Richard, K., Blanquicett, C., Milano, G., Blesius, A., Durand, A., Seitz, J.F.,
Favre, R., and Lacarelle, B. (2006): A rapid and inexpensive method
for anticipating severe toxicity to fluorouracil and fluorouracil-based
chemotherapy.
Cancer
, 28: 678-685.
9. Collie-Duguid, E.S., Etienne, M.C., Milano, G., and McLeod, H.L. (2000):
Known variant DPYD alleles do not explain DPD deficiency in cancer
patients.
Ther. Drug Monit.
, 10: 217-223.
10. Diasio, R.B., Beavers, T.L., and Carpenter, J.T. (1988): Familial deficiency
of dihydropyrimidine dehydrogenase. Biochemical basis for familial
pyrimidinemia and severe 5-fluorouracil-induced toxicity.
Pharmacogenetics
J. Clin.
, 81: 47-51.
11. Dobritzsch, D., Schneider, G., Schnackerz, K.D., and Lindqvist, Y.
(2001): Crystal structure of dihydropyrimidine dehydrogenase, a
major determinant of the pharmacokinetics of the anti-cancer drug
5-fluorouracil.
Invest
, 20: 650-660.
12. Etienne, M.C., Cheradame, S., Fischel, J.L., Formento, P., Dassonville, O.,
Renee, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. (1995):
Response to fluorouracil therapy in cancer patients: the role of tumoral
EMBO J.
